Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD: Elacestrant vs Standard of Care in ER+/HER2- Advanced Breast Cancer
NCT03778931Phase 3Completed
- Sponsor
- Stemline Therapeutics
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Molecular Glues
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Elacestrant with Standard of Care (SoC) (2 arms). Primary endpoints: Progression-free Survival in ESR1-mut Participants up to 12 months and Progression-free Survival in All Participants up to 12 months. Started May 2019; status: completed.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03778931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778931.